{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:12:30Z","timestamp":1787958750285,"version":"build-2784847793"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T00:00:00Z","timestamp":1600905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FIS2016-77692-C2-2-P"],"award-info":[{"award-number":["FIS2016-77692-C2-2-P"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PCIN-2017-098"],"award-info":[{"award-number":["PCIN-2017-098"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CGL2016-80833-R"],"award-info":[{"award-number":["CGL2016-80833-R"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002878","name":"Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["RNM1897"],"award-info":[{"award-number":["RNM1897"]}],"id":[{"id":"10.13039\/501100002878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002878","name":"Consejer\u00eda de Econom\u00eda, Innovaci\u00f3n, Ciencia y Empleo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["P18-RT-3786"],"award-info":[{"award-number":["P18-RT-3786"]}],"id":[{"id":"10.13039\/501100002878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Praziquantel is an antiparasitic drug indicated for the treatment of the schistosomiasis disease. This drug has very low aqueous solubility, requiring high oral doses for its administration which gives rise to side effects, therapeutic noncompliance and the appearance of resistant forms of the parasite. Clay minerals, like sepiolite and montmorillonite, are innocuous, non-toxic, biocompatible and low-cost excipients. Additionally, clays have high adsorbent properties that allow them to encapsulate drugs in nanometric spaces present in the channels in the case of the sepiolite or between the layers in the case of the montmorillonite. The interactions between the drug and clay minerals are studied experimentally with the strategy for preparing interactions products in organic solvents (ethanol, acetonitrile and dichloromethane) so that the interaction will be more effective and will be enhanced the aqueous solubility of praziquantel. The results showed that in the interaction products, the drug interacted with both clay minerals, which produced the loss of the crystallinity of the drug demonstrated by different techniques. This led to a significant increase in the dissolution rate of the praziquantel in all the interaction products in the simulated gastrointestinal tract media, except for the praziquantel\u2013montmorillonite product prepared in dichloromethane that presented a controlled release in acid medium. Moreover, in vitro cytotoxicity and cell cycle studies were performed in the interaction products prepared with ethanol. The interaction product with sepiolite was biocompatible with the HTC116 line cells, and it did not produce alterations in the cell cycle. However, interaction products with montmorillonite did not produce cell death, but they showed affectation and damage of cells in the cell cycle study at the highest concentration tested (20\u2013100 \u00b5M). Therefore, the different organic solvents used are adequate for the improvement of the biopharmaceutical profile of praziquantel. Drug\u2013clay interaction products, specifically with sepiolite, showed very promising results in which new accelerated oral release systems of the praziquantel were obtained.<\/jats:p>","DOI":"10.3390\/pharmaceutics12100914","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T04:18:57Z","timestamp":1600921137000},"page":"914","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Praziquantel\u2013Clays as Accelerated Release Systems to Enhance the Low Solubility of the Drug"],"prefix":"10.3390","volume":"12","author":[{"given":"Ana","family":"Borrego-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Instituto Andaluz de Ciencias de la Tierra, CSIC-University of Granada, Av. de las Palmeras 4, 18100 Granada, Spain"},{"name":"Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Campus de Cartuja s\/n, 18071 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"S\u00e1nchez-Espejo","sequence":"additional","affiliation":[{"name":"Instituto Andaluz de Ciencias de la Tierra, CSIC-University of Granada, Av. de las Palmeras 4, 18100 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0840-650X","authenticated-orcid":false,"given":"F\u00e1tima","family":"Garc\u00eda-Vill\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Campus de Cartuja s\/n, 18071 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Viseras","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, Campus de Cartuja s\/n, 18071 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8612-3826","authenticated-orcid":false,"given":"C. Ignacio","family":"Sainz-D\u00edaz","sequence":"additional","affiliation":[{"name":"Instituto Andaluz de Ciencias de la Tierra, CSIC-University of Granada, Av. de las Palmeras 4, 18100 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,24]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WTO) (2020, June 01). Available online: https:\/\/www.who.int\/neglected_diseases\/en\/."},{"key":"ref_2","unstructured":"World Health Organization (WTO) (2020, June 01). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0001-706X(00)00122-4","article-title":"The global status of schistosomiasis and its control","volume":"77","author":"Chitsulo","year":"2000","journal-title":"Acta Trop."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(06)70521-7","article-title":"Schistosomiasis and water resources development: Systematic review, meta-analysis, and estimates of people at risk","volume":"6","author":"Steinmann","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00436-012-3151-z","article-title":"Susceptibility or resistance of praziquantel in human schistosomiasis: A review","volume":"111","author":"Wang","year":"2012","journal-title":"Parasitol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0163-7258(85)90020-8","article-title":"Praziquantel: Mechanisms of anti-schistosomal activity","volume":"29","author":"Andrews","year":"1985","journal-title":"Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1002\/jps.20211","article-title":"Structural characterization and enantioseparation of the chiral compound praziquantel","volume":"93","author":"Liu","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejps.2016.04.023","article-title":"Molecular and crystal structure of praziquantel. Spectroscopic properties and crystal polymorphism","volume":"92","author":"Viseras","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (FDA) (2020, June 01). Available online: https:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm128219.htm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijpharm.2005.01.033","article-title":"In vitro characterization of some biopharmaceutical properties of praziquantel","volume":"295","author":"Rivera","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1572-4352(05)01001-9","article-title":"General introduction: Clays, clay minerals, and clay science","volume":"Volume 1","author":"Bergaya","year":"2006","journal-title":"Developments in Clay Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1346\/CCMN.2006.0540610","article-title":"Summary of recommendations of nomenclature committees relevant to clay mineralogy: Report of the Association Internationale Pour l\u2019Etude des Argiles (AIPEA) nomenclature committee for 2006","volume":"54","author":"Guggenheim","year":"2006","journal-title":"Clays Clay Miner."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1573-4285(04)80044-9","article-title":"Pharmaceutical and Cosmetic Applications of Clays","volume":"1","author":"Viseras","year":"2004","journal-title":"Interface Sci. Technol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clay.2005.03.007","article-title":"Influence of dispersion conditions of two pharmaceutical grade clays on their interaction with some tetracyclines","volume":"30","author":"Aguzzi","year":"2005","journal-title":"Appl. Clay Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clay.2006.06.015","article-title":"Use of clays as drug delivery systems: Possibilities and limitations","volume":"36","author":"Aguzzi","year":"2007","journal-title":"Appl. Clay Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clay.2010.01.007","article-title":"Current challenges in clay minerals for drug delivery","volume":"48","author":"Viseras","year":"2010","journal-title":"Appl. Clay Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejpb.2018.09.028","article-title":"Conformational polymorphic changes in the crystal structure of the chiral antiparasitic drug praziquantel and interactions with calcium carbonate","volume":"132","author":"Carazo","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pharmaceutics11100533","article-title":"Ground calcium carbonate as a low cost and biosafety excipient for solubility and dissolution improvement of praziquantel","volume":"11","author":"Albertini","year":"2019","journal-title":"Pharmaceutics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/pharmaceutics10040167","article-title":"Porous inorganic carriers based on silica, calcium carbonate and calcium phosphate for controlled\/modulated drug delivery: Fresh outlook and future perspectives","volume":"10","author":"Trofimov","year":"2018","journal-title":"Pharmaceutics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10847-010-9852-y","article-title":"Computational analysis and physico-chemical characterization of an inclusion compound between praziquantel and methyl-\u03b2-cyclodextrin for use as an alternative in the treatment of schistosomiasis","volume":"70","author":"Rodrigues","year":"2010","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1208\/s12249-009-9346-7","article-title":"Effect of cyclodextrin complexation on the aqueous solubility and solubility\/dose ratio of praziquantel","volume":"10","author":"Maragos","year":"2009","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5173(98)00382-2","article-title":"Improvement of the in vitro dissolution of praziquantel by complexation with \u03b1-, \u03b2-, and \u03b3-cyclodextrins","volume":"179","author":"Becket","year":"1999","journal-title":"Int. J. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1248\/cpb.47.1629","article-title":"Preparation, dissolution and characterization of Praziquantel solid dispersions","volume":"47","author":"Torrado","year":"1999","journal-title":"Chem. Pharm. Bull."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ijpharm.2016.08.009","article-title":"Unexpected solvent impact in the crystallinity of praziquantel\/poly(vinylpyrrolidone) formulations. A solubility, DSC and solid-state NMR study","volume":"511","author":"Costa","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2006.03.028","article-title":"Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel","volume":"318","author":"Passerini","year":"2006","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s13346-018-0487-7","article-title":"Dissolution and oral bioavailability enhancement of praziquantel by solid dispersions","volume":"8","author":"Liu","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpharm.2009.12.010","article-title":"In vitro and in vivo evaluation of praziquantel loaded implants based on PEG\/PCL blends","volume":"387","author":"Cheng","year":"2010","journal-title":"Int. J. Pharm."},{"key":"ref_29","first-page":"163","article-title":"Development and evaluation of praziquantel solid dispersions in sodium starch glycolate","volume":"12","author":"Chaud","year":"2013","journal-title":"Trop. J. Pharm. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijpharm.2005.02.009","article-title":"Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes","volume":"295","author":"Mourao","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105197","DOI":"10.1016\/j.clay.2019.105197","article-title":"Layered double hydroxides of CaAl: A promising drug delivery system for increased dissolution rate and thermal stability of praziquantel","volume":"180","author":"Melo","year":"2019","journal-title":"Appl. Clay Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.04875-14","article-title":"Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine schistosoma mansoni infection. antimicrob","volume":"59","author":"Mohamed","year":"2015","journal-title":"Agents Chemother."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.clay.2017.12.024","article-title":"Biopharmaceutical improvement of praziquantel by interaction with montmorillonite and sepiolite","volume":"160","author":"Carazo","year":"2018","journal-title":"Appl. Clay Sci."},{"key":"ref_34","unstructured":"Sainz-D\u00edaz, C.I., Borrego-S\u00e1nchez, A., Viseras, C., and Aguzzi, C. (2019). Method for Preparing a Nano-Structured Material of Praziquantel and a Silicate, Material Obtained and Use as an Antiparasitic. (Patent WO\/2020\/012044)."},{"key":"ref_35","first-page":"241","article-title":"La liberaci\u00f3n como factor limitativo de la absorci\u00f3n gastrointestinal","volume":"Volume 2","author":"Lauroba","year":"1998","journal-title":"Biofarmacia y Farmacocin\u00e9tica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0169-409X(01)00116-8","article-title":"Mathematical modeling of bioerodible, polymeric drug delivery systems","volume":"48","author":"Siepman","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijbiomac.2018.12.205","article-title":"Chitosan\/beidellite nanocomposite as diclofenac carrier","volume":"126","author":"Cheikh","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","article-title":"A new look at the statistical model identification","volume":"19","author":"Akaike","year":"1974","journal-title":"IEEE Trans. Automat. Contr."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1006\/abio.1994.1184","article-title":"A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry","volume":"218","author":"Gong","year":"1994","journal-title":"Anal. Biochem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0099-5428(08)60760-1","article-title":"Praziquantel","volume":"Volume 25","author":"Florey","year":"1998","journal-title":"Analytical Profiles of Drug Substances and Excipients"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jddst.2019.01.014","article-title":"Disodium salt of glycyrrhizic acid\u2013A novel supramolecular delivery system for anthelmintic drug praziquantel","volume":"50","author":"Meteleva","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00894-017-3266-3","article-title":"Molecular modeling and infrared and Raman spectroscopy of the crystal structure of the chiral antiparasitic drug Praziquantel","volume":"23","year":"2017","journal-title":"J. Mol. Model."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"105774","DOI":"10.1016\/j.clay.2020.105774","article-title":"Molecular interactions of praziquantel drug with nanosurfaces of sepiolite and montmorillonite","volume":"197","author":"Viseras","year":"2020","journal-title":"Appl. Clay Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0169-1317(98)00050-7","article-title":"Pharmaceutical applications of some Spanish clays (sepiolite, palygorskite, bentonite): Some preformulation studies","volume":"14","author":"Viseras","year":"1999","journal-title":"Appl. Clay Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-2031(01)00110-2","article-title":"Near-infrared and mid-infrared spectroscopic study of sepiolites and palygorskites","volume":"27","author":"Frost","year":"2001","journal-title":"Vib. Spectrosc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.theochem.2009.02.013","article-title":"Crystal structure and hydroxyl group vibrational frequencies of phyllosilicates by DFT methods","volume":"912","year":"2009","journal-title":"Theochem. J. Mol. Struct."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.2042-7158.1972.tb08930.x","article-title":"Letters to the editor: Linearization of dissolution rate curves by the Weibull distribution","volume":"24","author":"Langenbucher","year":"1972","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_49","first-page":"293","article-title":"Wide applicability","volume":"103","author":"Weibul","year":"1951","journal-title":"J. Appl. Mech."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1021\/ie50260a018","article-title":"Dependence of reaction velocity surface and agitation","volume":"23","author":"Hixson","year":"1931","journal-title":"Ind. Eng. Chem."},{"key":"ref_51","first-page":"236","article-title":"Dissolution rate studies. II. Dissolution of particles under conditions of rapid agitation","volume":"52","author":"Neibergall","year":"1963","journal-title":"J. Pharm. Sci."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/10\/914\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:13:05Z","timestamp":1760177585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/10\/914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,24]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["pharmaceutics12100914"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12100914","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,24]]}}}